Key result
There was no significant association between blood pressure and the levels of brain natriuretic peptide or copeptin in pregnant women with chronic hypertension already on antihypertensive treatment.
Why the study?
Studies assessing the clinical value of BNP and copeptin in pregnant women with chronic hypertension are sparse.
Do brain natriuretic peptide (BNP) and copeptin levels correlate with blood pressure in pregnant women with chronic hypertension on antihypertensive therapy?
Cross-Sectional (n=160)
No
Do brain natriuretic peptide (BNP) and copeptin levels correlate with blood pressure in pregnant women with chronic hypertension on antihypertensive therapy?
BNP and copeptin levels do not significantly correlate with blood pressure in pregnant women with chronic hypertension on antihypertensive therapy, suggesting these biomarkers may not be useful for monitoring BP control in this population.
Answers are grounded in this paper and cite their sources.
No association found between BNP/copeptin and BP in treated chronic hypertensive pregnancies; leaves open biomarker utility pending prospective studies.
BACKGROUND: Hypertensive disorders of pregnancy including preexisting (or chronic) hypertension are the most common complication encountered during pregnancy that contribute significantly to maternal and perinatal morbidity and mortality. Brain natriuretic peptide (BNP) and copeptin have been investigated as biomarkers in various hypertensive disorders, but studies of their clinical value in chronic hypertensive pregnant women are sparce. This study aimed to assess the levels of BNP and copeptin in chronic hypertensive pregnant women and investigate their correlation with blood pressure (BP) in chronic hypertensive pregnant women in South Western Nigeria. METHODS: One hundred and sixty consenting pregnant women in their third trimester of pregnancy, grouped into those with chronic hypertension (n = 80) and normotensive (n = 80), were recruited for this cross-sectional study. Age and clinical characteristics were obtained, and blood was aseptically drawn for BNP and copeptin measurement using enzyme-linked immunosorbent assay. Data was analyzed with IBM SPSS ver. 20.0. Data was analyzed using Student t-test, chi-square, and Pearson correlation test as appropriate. Statistical significance was set at P < 0.05. RESULTS: The mean systolic BP (SBP) and diastolic BP (DBP) were significantly higher in pregnant women with chronic hypertension (158.30 ± 3.51 and 105.08 ± 2.47 mmHg, respectively) compared with normotensive pregnant women (100.72 ± 3.02 and 70.29 ± 1.96 mmHg, respectively). The mean levels of BNP and copeptin were higher in pregnant women with chronic hypertension (57.26 ± 3.65 pg/mL and 12.44 ± 1.02 pmol/L, respectively) compared with normotensive pregnant women (49.85 ± 2.44 pg/mL and 10.25 ± 1.50 pmol/L, respectively) though not statistically significant. Correlations observed between SBP and DBP with levels of BNP (r = 0.204, P = 0.200; r = 0.142, P = 0.478) and copeptin (r = - 0.058, P = 0.288; r = 0.045, P = 0.907) were not statistically significant. CONCLUSIONS: There was no association between BP and the levels of BNP and copeptin in pregnant women with chronic hypertension who were already on antihypertensive treatment, with the implication that antihypertensive treatment may modulate BNP and copeptin release despite significantly elevated BP levels.
No takes yet. Share an insight, caveat, or question.
Okwor et al. (2022) conducted a cross-sectional in Chronic hypertension in pregnancy (n=160). Chronic hypertension vs. Normotensive pregnant women was evaluated on Mean brain natriuretic peptide (BNP) level (pg/mL) (p=0.093). There was no significant association between blood pressure and the levels of brain natriuretic peptide or copeptin in pregnant women with chronic hypertension already on antihypertensive treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: